Blood Pressure Medication Recall 2019: Another Expanded Losartan Recall For Cancer-Causing Impurity

Following an expanded blood pressure medication recall by Torrent Pharmaceuticals, Legacy Pharmaceutical Packaging, LLC has also expanded is Losartan tablets USP 50 mg recall to include one additional lot of medication. The blood pressure medication has been recalled for a possible impurity, which could be cancer-causing.

The recalled Losartan tablets may have trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA), a potential human carcinogen that could lead to cancer. The recall affects 30 count bottles with an NDC number of 68645-494-54. It was manufactured by Hetero Labs Limited.

Labels of the product can be viewed here.

The medication is used to treat high blood pressure and congestive heart failure. The full Legacy recall affects four repackaged lots of medication. A full list of recalled Legacy blood pressure medication can be viewed here.

The recalled blood pressure medication was distributed nationwide.

Consumers with questions about the recall can contact Inmar Pharmaceutical Services at 1-877-538-8443, Monday through Friday from 9 a.m. to 5 p.m. EST. Consumers should also contact their healthcare provider if they experience any issues related to the recalled medication.

Legacy has not received any reports of adverse effects due to the recall. The recall has been made in conjunction with the U.S. Food and Drug Administration.